Press Release

 Email this articleGovernment Homepage

Suspension of sale of anti-inflammatory drug
Bextra in HK


    In response to media enquiries on the request made by the Food and Drug Administration (FDA) of the United States of the voluntarily withdrawal of a non-steroidal anti-inflammatory drug "Bextra" by the drug company concern, a spokesman of the Department of Health today (April 8) made the following remarks:

    The Department of Health refers to Pfizer (USA)'s advice that patients should stop taking Bextra and contact their physicians about appropriate treatment options. The advice was given in response to the concern of the increased risk of cardiovascular toxicity and severe skin reactions in patients taking Bextra.

    In Hong Kong, the importer of Bextra, Pfizer Corporation Hong Kong Ltd., has agreed to immediately stop the sale of it which is a prescription-only medicine.

    For the time being, members of the public who have been taking Bextra should stop using it and contact their doctors for appropriate alternative medication.

    The department is closely monitoring the outcome of the review of the safety of Bextra.

Ends/Friday, April 8, 2005


Email this article